What tests are included in the newborn screening blood test in Florida, specifically the Newborn Screening (NBS) panel?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

In Florida, newborn blood screening includes tests for over 50 disorders, prioritizing early detection and treatment to prevent serious health complications, developmental delays, or even death, as recommended by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) 1. The Florida Newborn Screening Program tests for various disorders, including:

  • Metabolic disorders like phenylketonuria (PKU), maple syrup urine disease, and galactosemia
  • Endocrine disorders such as congenital hypothyroidism and congenital adrenal hyperplasia
  • Hemoglobinopathies including sickle cell disease and other hemoglobin variants
  • Cystic fibrosis
  • Severe combined immunodeficiency (SCID)
  • Critical congenital heart defects
  • Amino acid disorders, fatty acid oxidation disorders, organic acid disorders, and lysosomal storage disorders, as detected by tandem mass spectrometry 1 These tests are performed using a few drops of blood collected from the baby's heel within 24-48 hours after birth. The use of tandem mass spectrometry in newborn screening has substantially increased the number of metabolic disorders that can be detected from dried blood spot specimens 1. Early detection through these screenings allows for prompt intervention and treatment, potentially preventing serious health complications, developmental delays, or even death. Parents should ensure their newborn receives this screening and follow up with their pediatrician regarding the results, which are typically available within 7-14 days after testing. It is essential to note that while mass spectrometry can detect various disorders, it cannot replace current programs to screen for biotinidase deficiency, hypothyroid-hemoglobinopathies, virilizing adrenal hyperplasia, and galactosemia, which must be detected by other means 1.

From the Research

Newborn Blood Test in Florida

The specific tests included in the newborn blood test in Florida are not directly mentioned in the provided studies. However, the studies do provide information on the common disorders screened for in newborns:

  • Phenylketonuria 2, 3, 4, 5, 6
  • Congenital hypothyroidism 2, 3, 4, 5, 6
  • Cystic fibrosis 3, 4, 5, 6
  • Galactosemia 3, 4, 5
  • Medium-chain acyl-CoA dehydrogenase deficiency 3, 4, 5
  • Glutaryl-CoA dehydrogenase deficiency 3
  • Congenital adrenal hyperplasia 3, 4, 5, 6
  • Biotinidase deficiency 4, 5
  • Congenital hearing loss 4, 5
  • Homocystinuria 4, 5, 6
  • Maple syrup urine disease 4, 5, 6
  • Sickle cell disease and other hemoglobinopathies 4, 5, 6
  • Tyrosinemia 4, 5, 6
  • Isovaleric and glutaric type I acidurias 6
  • Disorders of fatty acid metabolism (MCADD, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD), and primary carnitine deficiency) 6

Disorders Screened in Newborns

The studies also mention that the newborn screening system consists of several parts, including newborn testing, follow-up of abnormal screening results, diagnostic testing, disease management, and continuous evaluation and improvement of the newborn screening system 4, 5. Additionally, the studies discuss the importance of informed consent, tandem mass spectrometry, and DNA analysis in newborn screening 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Screening for metabolic disorders. How are we doing?

Pediatric clinics of North America, 1993

Research

Newborn screening.

Pathology, 2008

Research

Newborn screening fact sheets.

Pediatrics, 2006

Research

[Newborn screening in France: news and perspectives].

Annales de biologie clinique, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.